Kiadis Pharma launches a private placement of approximately 3.7 million new shares
Amsterdam, The Netherlands, October 18, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces the launch of a private placement of approximately 3.7 million new shares to institutional investors, representing approximately 18% of the Company's current issued share capital (the "Placing"). Existing shareholders of the Company will not have pre-emptive rights in relation to the new shares to be issued. The new shares will rank pari passu in all respects with the currently outstanding shares of the Company.
Kiadis Pharma intends to use the net proceeds of the Placing to:
continue the Phase 3 international, randomized, controlled, multi-centre clinical trial for ATIR101 in the United States, Canada and Europe;
further prepare for commercialization in Europe by investing into market access preparation, reimbursement, commercial organization and commercial manufacturing;
apply funds for general corporate purposes and other working capital needs.
The new shares will be placed with institutional investors through an accelerated bookbuilding process and the subscription price and the number of shares to be issued in the Placing will be determined through this process. The bookbuilding period for the Placing will commence today with immediate effect and will close at short notice.
In relation to the Placing, the Company has, subject to customary exceptions, agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share issuances. In addition, and also subject to customary exceptions, the largest shareholders of the Company (funds represented by and/or affiliated with Life Sciences Partners and Draper Esprit, together representing 36.2% of the share capital of the Company) as well as all members of the Company's Management Board and Supervisory Board have agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share disposals.
The Company will announce the final number of new shares placed and the subscription price in the Placing in a subsequent press release expected to be published before the beginning of trading on Euronext Amsterdam and Brussels on Friday, October 19, 2018.
Jefferies International Limited ("Jefferies") is acting as Global Coordinator. Jefferies and Kempen & Co N.V. are acting as Joint Bookrunners and KBC Securities N.V. and Oppenheimer & Co. Inc. are acting as Co-Managers in connection with the Placing. Saola Healthcare Partners is acting as financial advisor to the Company.
For more information, please contact:
Kiadis Pharma:
Karl Hård, Head of IR & Communications